These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 35908450)

  • 21. Factors associated with fingolimod rebound: A single center real-life experience.
    Goncuoglu C; Tuncer A; Bayraktar-Ekincioglu A; Ayvacioglu Cagan C; Acar-Ozen P; Cakan M; Karabulut E; Karabudak R
    Mult Scler Relat Disord; 2021 Nov; 56():103278. PubMed ID: 34655957
    [TBL] [Abstract][Full Text] [Related]  

  • 22. What happens after fingolimod discontinuation? A multicentre real-life experience.
    Landi D; Signori A; Cellerino M; Fenu G; Nicoletti CG; Ponzano M; Mancuso E; Fronza M; Ricchiuto ME; Boffa G; Inglese M; Marfia GA; Cocco E; Frau J
    J Neurol; 2022 Feb; 269(2):796-804. PubMed ID: 34136943
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of multiple sclerosis patients with or without rebound activity after fingolimod cessation: Five-year clinical outcomes.
    Gulec B; Everest E; Gorkey OD; Koc M; Tutuncu M; Saip S; Siva A; Uygunoglu U
    Eur J Neurol; 2023 Sep; 30(9):2745-2751. PubMed ID: 37300847
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment.
    Aslanyan A; Anwar-Hashim Z; Siripurapu R; Mihalova T
    BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term real-world effectiveness and safety of fingolimod over 5 years in Germany.
    Ziemssen T; Lang M; Schmidt S; Albrecht H; Klotz L; Haas J; Lassek C; Lang S; Winkelmann VE; Ettle B; Schulze-Topphoff U;
    J Neurol; 2022 Jun; 269(6):3276-3285. PubMed ID: 34982201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumefactive multiple sclerosis in association with fingolimod initiation and discontinuation.
    Croteau D; Tobenkin A; Brinker A; Kortepeter CM
    Mult Scler; 2021 May; 27(6):903-912. PubMed ID: 32662718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod.
    Evangelopoulos ME; Miclea A; Schrewe L; Briner M; Salmen A; Engelhardt B; Huwiler A; Chan A; Hoepner R
    CNS Neurosci Ther; 2018 Oct; 24(10):984-986. PubMed ID: 29898493
    [No Abstract]   [Full Text] [Related]  

  • 28. Autoimmune hemolytic anemia after treatment with fingolimod in a patient with multiple sclerosis (MS): A case report and review of the literature.
    Najdaghi S; Davani DN; Ghajarzadeh M; Shaygannejad V
    Autoimmun Rev; 2022 Dec; 21(12):103203. PubMed ID: 36220524
    [No Abstract]   [Full Text] [Related]  

  • 29. Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis.
    Fox E; Vieira MC; Johnson K; Peeples M; Bensimon AG; Signorovitch J; Herrera V
    J Neurol Sci; 2019 Mar; 398():163-170. PubMed ID: 30731303
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis.
    Yang T; Tian X; Chen CY; Ma LY; Zhou S; Li M; Wu Y; Zhou Y; Cui YM
    Br J Clin Pharmacol; 2020 Apr; 86(4):637-645. PubMed ID: 31869429
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder.
    Lin W; Chou CH; Yang FC; Tsai CK; Lin YK; Sung YF
    Front Immunol; 2023; 14():1115120. PubMed ID: 37122715
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry.
    Meca-Lallana JE; Oreja-Guevara C; Muñoz D; Olascoaga J; Pato A; Ramió-Torrentà L; Meca-Lallana V; Hernández MA; Marzo ME; Álvarez-Cermeño JC; Rodríguez-Antigüedad A; Montalbán X; Fernández O;
    PLoS One; 2021; 16(10):e0258437. PubMed ID: 34644366
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Severe disease exacerbations in patients with multiple sclerosis after discontinuing fingolimod.
    Członkowska A; Smoliński Ł; Litwin T
    Neurol Neurochir Pol; 2017; 51(2):156-162. PubMed ID: 28209440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-world effectiveness and safety of fingolimod in patients with multiple sclerosis in the Czech Republic: results from core and extension parts of the GOLEMS study up to 48 months.
    Tichá V; Počíková Z; Vytlačil J; Štěpánová R
    BMC Neurol; 2022 Apr; 22(1):143. PubMed ID: 35428205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Finnish multiple sclerosis patients treated with cladribine tablets: a nationwide registry study.
    Rauma I; Viitala M; Kuusisto H; Atula S; Sipilä JOT; Ryytty M; Soilu-Hänninen M; Järvinen E
    Mult Scler Relat Disord; 2022 May; 61():103755. PubMed ID: 35483129
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein Barr virus infection reactivation as a possible trigger of primary biliary cirrhosis-like syndrome in a patient with multiple sclerosis in the course of fingolimod treatment.
    Marrone A; Signoriello E; Alfieri G; Dalla Mora L; Rinaldi L; Rainone I; Adinolfi LE; Lus G
    Infez Med; 2014 Dec; 22(4):331-6. PubMed ID: 25551852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complicated Monkeypox Infection in a Patient With Multiple Sclerosis and Fingolimod Treatment.
    Müller-Jensen L; Kriedemann H; Anvari K; Huehnchen P; Siffrin V
    Neurology; 2023 Apr; 100(14):670-671. PubMed ID: 36539295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy.
    Navardi S; Sahraian MA
    Mult Scler Relat Disord; 2018 Apr; 21():69-70. PubMed ID: 29474980
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports.
    Forci B; Mariottini A; Mechi C; Massacesi L; Repice A
    Mult Scler Relat Disord; 2017 Jul; 15():24-26. PubMed ID: 28641768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy.
    Hellwig K; Tokic M; Thiel S; Hemat S; Timmesfeld N; Ciplea AI; Gold R; Langer-Gould AM
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37217309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.